Trial Profile
A Randomized, Double-Blind, Placebo-Controlled Study in Subjects With Rheumatoid Arthritis to Evaluate the Safety, Tolerability and Pharmacokinetics of Multiple Doses of ABBV-257
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs ABBV 257 (Primary)
- Indications Rheumatoid arthritis
- Focus Adverse reactions; Pharmacokinetics
- Sponsors AbbVie
- 01 Mar 2016 Status changed from active, no longer recruiting to completed, according to ClinicalTrials.gov record.
- 28 Aug 2015 New trial record
- 26 Aug 2015 Planned number of patients changed from 24 to 8 as reported by ClinicalTrials.gov.